LOVE — Cannara Biotech Balance Sheet
0.000.00%
- CA$157.26m
- CA$190.33m
- CA$82.15m
- 71
- 87
- 78
- 93
Annual balance sheet for Cannara Biotech, fiscal year end - August 31st, CAD millions except per share, conversion factor applied.
2020 August 31st | 2021 August 31st | 2022 August 31st | 2023 August 31st | 2024 August 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 7.77 | 8.16 | 12.1 | 4.27 | 6.62 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.309 | 2.97 | 8.62 | 10.6 | 13 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 10.5 | 19.2 | 41 | 51.7 | 67.5 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 43.6 | 71.7 | 83.4 | 89.4 | 84.9 |
| Net Intangible Assets | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 54.9 | 92 | 126 | 142 | 155 |
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 3.48 | 6.83 | 11.9 | 21.2 | 27 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 16.5 | 27.9 | 58.9 | 61.8 | 66.8 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 38.4 | 64.1 | 66.7 | 79.7 | 88 |
| Total Liabilities & Shareholders' Equity | 54.9 | 92 | 126 | 142 | 155 |
| Total Common Shares Outstanding |